**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75122

**Manuscript Type:** MINIREVIEWS

**Shared decision-making in the management of patients with inflammatory bowel disease**

Song K *et al*. Shared decision-making in IBD management

Kai Song, Dong Wu

**Kai Song, Dong Wu,** Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China

**Author contributions:** Song K proposed the article framework and performed the majority of the writing; and Wu D settled down the outline and revised the article

**Supported by** Peking Union Medical College, No. 2019zlgc0503.

**Corresponding author: Dong Wu, MD, Professor,** Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. wudong@pumch.cn

**Received:** January 16, 2022

**Revised:** April 21, 2022

**Accepted:** June 19, 2022

**Published online:** July 14, 2022

**Abstract**

The rapid progress of research into inflammatory bowel disease (IBD) has resulted in increasingly more treatment options. Different options have different advantages and disadvantages, and the preferences of patients may also differ. If patients can be invited to the formulation of medical decision-making, their compliance and satisfaction would be improved, thus possibly achieving better therapeutic results. The present review aims to summarize the current literature on shared decision-making (SDM) in the management of IBD, with the goal of promoting the application of SDM.

**Key Words:** Inflammatory bowel diseases; Decision making; Shared; Therapeutics

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. *World J Gastroenterol* 2022; 28(26): 3092-3100

**URL:** <https://www.wjgnet.com/1007-9327/full/v28/i26/3092.htm>

**DOI:** https://dx.doi.org/10.3748/wjg.v28.i26.3092

**Core Tip:** It is often challenging to make therapeutic decisions for patients with inflammatory bowel disease (IBD), given the uncertainty of therapeutic options and diverse patient values. Shared decision-making (SDM) is a process to formulate treatment with patients, trying to clarify and take account of the preferences of patients, increasing their compliance and satisfaction. We summarize current evidence and illustrate the necessity of applying SDM in IBD management.

**INTRODUCTION**

Inflammatory bowel disease (IBD) refers to a group of chronic inflammatory diseases of the gastrointestinal tract, mainly including Crohn’s disease (CD) and ulcerative colitis (UC), which are lifelong diseases that tend to affect individuals aged 20–40 years[1,2]. IBD affects nearly all aspects of living, including patients’ private, occupational and social lives. In total, 50%–80% of UC patients and about 67% of CD patients suffer from relapses and remissions, which is a clinical feature of IBD. Around 15%–30% of UC patients fail to achieve sustained remission, while only 13% of CD patients have a relapse-free course[3,4]. Therefore, IBD has a large socioeconomic burden, and direct and indirect costs caused by UC reach 0.81–1.49 billion dollars per year in the United States[5].

Previous research on the mechanism of IBD suggests that genetic susceptibility, intestinal microbiota, environmental factors (such as diet and stress), and the association between proinflammatory and anti-inflammatory cells and factors are involved in the occurrence and development of IBD[6,7]. An increasing number of therapeutic agents have been investigated, including the tumor necrosis factor (TNF)-α antagonist infliximab, and the effectiveness of these agents has been confirmed[8]. Although the large number of treatment options available for IBD is a positive aspect, it complicates the choice of optimal treatment for individual patients.

**TRADITIONAL THERAPEUTIC STRATEGIES**

The primary therapeutic aim for IBD is to induce and maintain remission[9], of which mucosal healing is the most important target[10]. Besides clinical remission, the most important objective is to achieve mucosal healing under endoscopy[1,2,9,11], which is associated with reduction in recurrence, surgical interventions, intestinal damage and steroid dependence[12,13]. The current treatment regimens for UC and CD are stratified according to severity. A step-up strategy is usually used to treat mild-to-moderate IBD[1,2,14]. For example, mild-to-moderate UC would be first subjected to 5-aminosalicylic acid (5-ASA). When efficacy is unsatisfactory, treatments are escalated to glucocorticoid and/or immunosuppressants, while biologicals are usually used as the final resort. By contrast, for severe IBD or steroid-refractory IBD, immunosuppressants or biologicals may be considered in the earlier stage.

Although the majority of patients with mild-to-moderate UC who receive 5-ASA achieved symptomatic relief within 8 wk, 41% of patients who achieve induced remission eventually experience relapse[15,16]. Thus, daily medication over a longer period of time is necessary to maintain remission. In addition, multiple daily doses of 5-ASA are required in the stage of induced remission, which may impair compliance, particularly for outpatients without regular medication reminders. Additionally, when 5-ASA administration is reduced to once daily during the induction or maintenance of remission stage[16,17], patient compliance may drop to 40%[18]. Poor compliance is a key obstacle for the induction and maintenance of remission[19].

Glucocorticoids constitute an important treatment for the induction of remission in active disease, particularly in CD. However, about 16% of CD patients do not respond to glucocorticoids after treatment for 30 d[20]. In addition, glucocorticoid therapy is often accompanied by a variety of side effects, including diabetes, hypertension, opportunistic infections, and osteoporosis[21,22]. More than 28% of patients with CD develop steroid dependence[20]. Glucocorticoids are not effective in maintaining remission, and the risks associated with long-term use are marked; thus, the dose of glucocorticoids needs to be tapered at the onset of clinical remission[9,16]. When mucosal remission is not achieved, complications such as fistula and stenosis can easily occur[23,24].

Contrary to traditional step-up therapy, the TOP-DOWN trial[25] confirmed that early combination of immunosuppressants led to a higher remission rate than standard step-up therapy in patients without steroids. Evidence has confirmed that the early use of biologicals may benefit certain patients with mild-to-moderate IBD[26]. The CHARM[27], SONIC[24], PRECISE 2[28] and GEMINI 2[29] trials demonstrated the advantages of early biological treatment over step-up therapy in patients with CD, involving anti-TNFα (infliximab and certolizumab) and anti-integrins (vedolizumab). Without sufficient evidence in patients with UC, previous studies showed lower remission rates in patients who had a shorter course of the disease[30], while other studies suggested that early use of vedolizumab increased remission in patients with UC[31].

However, no consensus has formed regarding the early use of biologicals for patients with mild-to-moderate IBD. The Pharmaceutical Benefits Scheme (PBS) of Australia specifies that biologicals should be considered only when the disease remains clinically active after 6 wk of steroids and 3 mo of immunosuppressants[9]. Despite current evidence supporting early use of biologicals, particularly for patients with CD, clinical decision-making needs to involve patients when treatment is economically demanding. It would be improper for clinicians to use biologicals at an early stage solely relying on the personal opinion of the physician, as it could generate conflicts between physicians and patients.

Refractory IBD patients with severe complications (uncontrolled hemorrhage, perforation, abscesses or malignancy) are candidates for surgery[1,2]. However, a previous study showed that gastroenterologists might differ from IBD patients in the willingness to surgery. Patients were more willing than gastroenterologists to take risks to undergo surgery, and surgeons agreed with patients in the majority of cases[32]. The differences in perceptions among physicians and surgeons have a marked impact on patients, including the timing of referral for surgery.

Due to the convenience of wide access to information, patients may have their own ideas about treatment. Ignoring patients’ values or preferences may lead to patient dissatisfaction, poor compliance, and eventually reduced treatment efficacy. Therefore, it is advisable to involve patients in decision-making and to discuss patients’ preference after they have been fully informed about the treatment options, which can share the risks and improve patients’ compliance. This is called shared decision-making (SDM).

**SDM**

SDM is an approach where clinicians and patients share the best available evidence when faced with decision-making, and that patients are supported to consider options to achieve informed preferences[33]. Different from traditional diagnosis and treatment procedures, SDM requires that clinicians provide alternative choices of examinations and treatments, and describe the associated risks and benefits, while patients express their preferences and values, and both sides ultimately make decisions that are appropriate and are consistent with patients’ best interests[34].

SDM consists of three key steps: (1) clinicians inform patients of alternative decisions and provide relevant, high-quality, accessible information; (2) clinicians consider the patients’ values and preferences, particularly the most desired therapeutic targets; and (3) physicians integrate the patients’ preferences and values into the decisions to be made[34-36]. The three-talk model is practical to distribute the aforementioned three steps into three conversations, including team talk, option talk and decision talk[37,38]. In the team talk, physicians first actively promote patient participation, inform patients of the current options available for consideration, help patients realize that this is a bidirectional treatment requiring their own participation, and allow patients to think about the primary therapeutic target. In the options talk, physicians introduce each choice to the patients in detail, including the associated advantages and disadvantages, so that patients can compare each option based on their values. For example, for patients with CD, it is necessary to discuss treatment options, such as medical, surgical, and endoscopic therapy, and evidence-based information should be used to explain the remission rate, risks, and costs of each option, so as to objectively demonstrate the advantages and disadvantages of each choice to allow the patients to balance the pros and cons of each approach according to their own preferences and values. In the decision talk, physicians should elicit the patients’ preferences and values; thus, the physicians need to understand what is most important to the patients, and make the appropriate decision together with the patients based on the patients’ preferences and values. It should be emphasized that it is a course of patients’ deliberation, from the stage of being aware of the options to that of understanding those options and having sufficient time to think about what is most important to them with the support of the physicians.

Decision aids can be used for patient education during SDM[39,40]. Decision aids are tools based on evidence-driven medical information. For example, patients can be intuitively told of the clinical remission rate of CD under infliximab monotherapy, and the approximate increased infection rate as well. These tools can be accessed online, on paper, or in video form[34,41,42], and aim to help patients to make deliberate choices among various treatment alternatives[43]. These tools can help patients to obtain relevant clinical evidence, include patients’ preferences when medical decision-making dilemmas occur, allow patients to understand the possible long- and short-term results, and promote high-quality decision-making. In terms of decision aids for biological agents, Almario *et al*[44] designed the online decision aid tool IBD and me, which covers the commonly used cetuzumab, viduzumab, adalimumab, infliximab, galimumab and eutecumab; and introduces the timing and frequency of biological use, route of administration, side effects (mainly infectious and oncogenic risks), and common adverse effects of hormones and immunosuppressants. A personalized decision preference report can be obtained after finishing the questionnaire online.

**SDM IN IBD**

Surveys have shown that the majority of IBD patients agree to be involved in decision-making, and want to be informed about alternative treatments[45-48]. The majority of patients who participate in SDM experience improved clinical satisfaction, higher trust in doctors, and better compliance[49-51]. However, SDM is not suitable for all cases. Medical decisions include effective decisions and preference-sensitive decisions[52]. For effective decisions, it has been demonstrated that the benefits outweigh the risks, so the decisions are undoubtedly the best strategy. For example, coloproctectomy is required in UC patients with complicated colorectal cancer. However, for preference-sensitive decisions, there is no sufficient evidence to demonstrate which treatment is the best, as there may be multiple reasonable treatment options (even including follow-up observation); thus, the judgement of the benefit/risk ratio falls upon patients, such as whether the treatment target they value has been achieved, or whether the side effects they are concerned about have occurred in the past. Of the two decision types, SDM only fits in the preference-sensitive decisions, which is often present in the management of IBD. IBD is a complex disease with large individual variation, and each treatment has particular advantages and disadvantages. Therefore, SDM is suitable for the management of IBD.

In addition to the aforementioned selection of step up therapy or top-down early intervention treatment strategy, SDM can be used for choosing biologicals. A number of biologicals are currently available for the treatment of IBD, including infliximab, adalimumab, certolizumab, golimumab, natalizumab, vedolizumab and ustekinumab, with differences in the mechanism, route of administration, and side effects[53]. However, it was not until 2019 that the first head-to-head VARSITY trial[54] compared the efficacy and safety of intravenous vedolizumab to subcutaneous adalimumab. Other head-to-head trials of different biologicals are still awaited[55]. Clinicians’ selection of biologicals especially for CD patients is varied, because the majority of real-world data on CD show no significant differences in clinical remission rate[56]. Under these circumstances, it is a preference-sensitive decision to choose biologicals. For example, infliximab is administered intravenously, while adalimumab is administered subcutaneously, thus the length of hospital stay varies. While infliximab is administered at intervals of 0, 2 and 6 wk to induce remission, and then administered every 8 wk, adalimumab is administered every 2 wk. In such a case, some patients may be more concerned with the frequency or route of administration due to the distance to the hospital, and therefore may choose infliximab treatment at longer intervals, whereas other patients may give priority to side effects. In a study involving 640 patients with IBD[44], factors that influenced the choice of biologicals for patients with UC were in the following order: long-term remission rate, route/frequency of administration, and risk of lymphoma. For patients with CD, these factors were short-term remission rate, risk of lymphoma, and route/frequency of administration. Of note, a small percentage of patients (3.6%) cited the mechanism of action as the primary factor for their selection of a given biological. At the same time, physicians’ assumption of patients’ acceptance of biologicals and their preferred route of administration differs from the patients’ opinion[57]. If doctors impose on their patients what they think is universally applicable instead of incorporating the patients’ preference into the decision-making process, patients may be forced to agree to a treatment plan against their own values. Patients who do not trust their doctors may develop a self-protective mechanism of rejection, thus leading to poor compliance. This awkward situation can be avoided to a large extent by involving patients in the decision-making process.

For the past 20 years, it has been discussed whether biologicals alone or in combination with immunosuppressants should be used for the treatment of IBD. The results of the SONIC study showed the advantages of the combination treatment[58]. Infliximab combined with immunosuppressants achieved higher rates of clinical remission and mucosal healing compared with infliximab or azathioprine alone in corticosteroid-free patients with CD. This may be associated with the fact that immunosuppressants reduce the generation of antidrug antibodies and increase the blood concentration of biological agents[58,59]. Although there is increasing evidence that combination treatment is superior to single-drug treatment[59-61], and the early use of infliximab with azathioprine or methotrexate for ≥ 1 year has been recommended[62], to date, not all the studies support the use of combination treatment, particularly in the case of biologicals other than infliximab[63-67]. In terms of safety, previous studies have shown that biologicals combined with immunosuppressants can increase the incidence of infection and malignancy[68-72]. Therefore, the benefit/risk ratio remains unclear regarding the combination of biological agents with immunosuppressants; thus, clinicians need to explain the benefits and risks to patients. More importantly, the preferences of the patients need to be considered to determine whether the patients would be willing to accept the risk of increased infection and tumor incidence to achieve an increase in remission rate. By involving patients in the decision-making process, the risk of increased side effects can be shared by both doctors and patients.

IBD patients have a risk of relapse after reduction or withdrawal of 5-ASA, glucocorticoids, immunosuppressants, biologicals, or combination therapy. Approximately 30% of patients with CD or UC who stop immunosuppressant monotherapy relapse within 2 years, while 50%–75% relapse within 5 years. By contrast, the risk of relapse after stopping anti-TNF therapy is 30%–40% at 1 year and > 50% at 2 years[73]. The therapeutic cost associated with the long-term use of aforementioned drugs is high, and some side effects may be related to the duration of use, such as the risk of cancer after the use of biologicals. Therefore, whether the treatment should be stopped or the dose tapered needs to be weighed with regard to the possible benefits, costs and risks, and decisions must be made individually. Given the high recurrence rate of IBD and the uncertainty about the optimal timing for clinical, biochemical and endoscopic follow-up, follow-up plans after drug withdrawal or dose reduction should also be made together with patients, taking their preferences into account[73].

As mentioned above, in addition to requiring informed consent, whether patients with IBD should undergo surgery also requires SDM. Controversies exist regarding the choice of surgery[74]. Ileal pouch–anal anastomosis (IPAA) has become the standard surgical option offered to patients with UC, with endoanal mucosal resection being the second choice. IPAA preserves the anal transition zone, which improves fecal continence. However, the elimination of colonic mucosa is the goal of surgical intervention; thus, what IPAA preserves will put the patient at risk of developing dysplasia and residual disease in the remaining anal canal epithelium, while mucosectomy can decrease dysplasia risk. Therefore, doctors and patients should balance the benefits against potential relapse and malignant change in the retained mucosa.

**DISCUSSION**

In multiple aspects of IBD management, SDM has shown potential. We believe that SDM can and should be used in IBD therapy (Figure 1). As mentioned, the treatment of IBD is a preference-sensitive choice; the advantages and disadvantages of which need to be weighed by the patients. Clinicians need to invite patients to the decision-making process, even though not all situations are suitable for SDM. For example, when perforation occurs in a UC patient with toxic megacolon, there is no doubt about the choice of treatment, but patients still need to be aware of the need to undergo surgery. Therefore, clinicians must determine whether it is a preference-sensitive decision and whether SDM is required. If patients decline to participate in the SDM even after multiple invitations by doctors, clinicians may not have to continue spending their time on persuading patients.

    SDM is a type of informed consent based on evidence-based medicine, putting forward certain requirements for doctors and patients. Challenges inevitably exist in the implementation of SDM. From the aspect of clinicians, as mentioned above, it is important to consider whether doctors are fully aware of the pros and cons of the drugs they choose as new treatments emerge and research advances rapidly. Although it can be resolved with the help of decision aids tools, the tools also should be updated continually. In addition, clinicians should have the awareness and techniques of SDM, and need to receive professional education. With the SDM skills, physicians’ willingness to impart relevant knowledge to patients should be emphasized. In addition, different perceptions of IBD between physicians and surgeons may influence patients’ perceptions. However, it is worth mentioning that diagnosis and treatment after discussion with a multidisciplinary team is a model that will help bridge the cognitive gap between physicians and surgeons. IBD patients’ preferences and disease patterns vary[44], meaning that no SDM plan fits all patients once and for all. Doctors need to be flexible, and patients need to have unlimited access to information and they should be actively invited to the decision-making process. The implementation of SDM undoubtedly needs policy support. For example, biologicals obtained in a first-tier city may not be available in other less-developed cities, which is a restriction for SDM. Unfortunately, SDM is not adequately addressed in current medical education, leading to less awareness of what it is and how to implement it. Therefore, we can’t emphasize it too much that the healthcare providers should be trained in their early stage of career to increase the benefits of implementing of SDM. And the early stage training hopefully will cultivate physicians’ habit unconsciously to take advantage of SDM in the medical practice.

These challenges need to be carefully considered before SDM can be implemented. Although SDM is theoretically suitable for patients with IBD, studies comparing SDM with traditional decision-making methods remain sparse and are eagerly awaited in the future. We hope that this review will promote the use of SDM in the management of IBD.

**CONCLUSION**

The investigations delineated in the present article revealed the dilemma of choosing individualized treatments for patients with IBD. We also discussed the advantages of SDM and the aspects in which SDM can be used. Current evidence showed the limitations of conventional step-up therapy for IBD. However, lack of head-to-head clinical trials and diverse treatment preferences of patients lead to difficulty of individualized decision-making. We demonstrate the latest advance of SDM with the support of clinical data, hoping that SDM will be better used by physicians caring for IBD patients.

**ACKNOWLEDGEMENTS**

We thank Pro. Ji Li for his comment upon this article.

**REFERENCES**

1 **Torres J**, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. *Lancet* 2017; **389**: 1741-1755 [PMID: 27914655 DOI: 10.1016/S0140-6736(16)31711-1]

2 **Ungaro R**, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet* 2017; **389**: 1756-1770 [PMID: 27914657 DOI: 10.1016/S0140-6736(16)32126-2]

3 **Holtmann MH**, Galle PR. Current concept of pathophysiological understanding and natural course of ulcerative colitis. *Langenbecks Arch Surg* 2004; **389**: 341-349 [PMID: 14760536 DOI: 10.1007/s00423-003-0448-5]

4 **Gajendran M**, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. *Dis Mon* 2018; **64**: 20-57 [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001]

5 **Cohen RD**, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. *Aliment Pharmacol Ther* 2010; **31**: 693-707 [PMID: 20064142 DOI: 10.1111/j.1365-2036.2010.04234.x]

6 **Guan Q**. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. *J Immunol Res* 2019; **2019**: 7247238 [PMID: 31886308 DOI: 10.1155/2019/7247238]

7 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

8 **Ngo B**, Farrell CP, Barr M, Wolov K, Bailey R, Mullin JM, Thornton JJ. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. *Curr Mol Pharmacol* 2010; **3**: 145-152 [PMID: 20799925 DOI: 10.2174/1874467211003030145]

9 **Wright EK**, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. *Med J Aust* 2018; **209**: 318-323 [PMID: 30257634 DOI: 10.5694/mja17.01001]

10 **Jeong DY**, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH, Shin JI. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. *Autoimmun Rev* 2019; **18**: 439-454 [PMID: 30844556 DOI: 10.1016/j.autrev.2019.03.002]

11 **Siegel CA**, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. *Gut* 2018; **67**: 244-254 [PMID: 27780886 DOI: 10.1136/gutjnl-2016-312648]

12 **Shah SC**, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. *Aliment Pharmacol Ther* 2016; **43**: 317-333 [PMID: 26607562 DOI: 10.1111/apt.13475]

13 **Shah SC**, Colombel JF, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2016; **14**: 1245-1255.e8 [PMID: 26829025 DOI: 10.1016/j.cgh.2016.01.015]

14 **Seyedian SS**, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. *J Med Life* 2019; **12**: 113-122 [PMID: 31406511 DOI: 10.25122/jml-2018-0075]

15 **Feagan BG**, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2012; **10**: CD000544 [PMID: 23076890 DOI: 10.1002/14651858.CD000544.pub3]

16 **Bressler B**, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. *Gastroenterology* 2015; **148**: 1035-1058.e3 [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001]

17 **Feagan BG**, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2012; **10**: CD000543 [PMID: 23076889 DOI: 10.1002/14651858.cd000543.pub3]

18 **Kane SV**, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. *Am J Gastroenterol* 2001; **96**: 2929-2933 [PMID: 11693328 DOI: 10.1111/j.1572-0241.2001.04683.x]

19 **Jackson B**, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 1079-1100 [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109]

20 **Faubion WA Jr**, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001; **121**: 255-260 [PMID: 11487534 DOI: 10.1053/gast.2001.26279]

21 **Rezaie A**, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, Kaplan GG, Seow CH. Budesonide for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2015: CD000296 [PMID: 26039678 DOI: 10.1002/14651858.CD000296.pub4]

22 **Benchimol EI**, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2008: CD006792 [PMID: 18425970 DOI: 10.1002/14651858.CD006792.pub2]

23 **Bouguen G**, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? *Gut* 2011; **60**: 1178-1181 [PMID: 21610273 DOI: 10.1136/gut.2010.234617]

24 **Peyrin-Biroulet L**, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. *Gut* 2014; **63**: 88-95 [PMID: 23974954 DOI: 10.1136/gutjnl-2013-304984]

25 **D'Haens G**, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet* 2008; **371**: 660-667 [PMID: 18295023 DOI: 10.1016/S0140-6736(08)60304-9]

26 **Berg DR**, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2019; **25**: 1896-1905 [PMID: 30934053 DOI: 10.1093/ibd/izz059]

27 **Schreiber S**, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. *J Crohns Colitis* 2013; **7**: 213-221 [PMID: 22704916 DOI: 10.1016/j.crohns.2012.05.015]

28 **Schreiber S**, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. *Am J Gastroenterol* 2010; **105**: 1574-1582 [PMID: 20234346 DOI: 10.1038/ajg.2010.78]

29 **Sandborn WJ**, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2013; **369**: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215739]

30 **Murthy SK**, Greenberg GR, Croitoru K, Nguyen GC, Silverberg MS, Steinhart AH. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. *Inflamm Bowel Dis* 2015; **21**: 2090-2096 [PMID: 26099066 DOI: 10.1097/MIB.0000000000000474]

31 **Feagan BG**, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. *Clin Gastroenterol Hepatol* 2017; **15**: 229-239.e5 [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044]

32 **Byrne CM**, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn's disease. *Dis Colon Rectum* 2007; **50**: 586-597 [PMID: 17380368 DOI: 10.1007/s10350-006-0847-0]

33 **Elwyn G**, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing shared decision making in the NHS. *BMJ* 2010; **341**: c5146 [PMID: 20947577 DOI: 10.1136/bmj.c5146]

34 **Barry MJ**, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. *N Engl J Med* 2012; **366**: 780-781 [PMID: 22375967 DOI: 10.1056/NEJMp1109283]

35 **Barratt A**. Evidence Based Medicine and Shared Decision Making: the challenge of getting both evidence and preferences into health care. *Patient Educ Couns* 2008; **73**: 407-412 [PMID: 18845414 DOI: 10.1016/j.pec.2008.07.054]

36 **Elwyn G**, Tsulukidze M, Edwards A, Légaré F, Newcombe R. Using a 'talk' model of shared decision making to propose an observation-based measure: Observer OPTION 5 Item. *Patient Educ Couns* 2013; **93**: 265-271 [PMID: 24029581 DOI: 10.1016/j.pec.2013.08.005]

37 **Elwyn G**, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, Tomson D, Dodd C, Rollnick S, Edwards A, Barry M. Shared decision making: a model for clinical practice. *J Gen Intern Med* 2012; **27**: 1361-1367 [PMID: 22618581 DOI: 10.1007/s11606-012-2077-6]

38 **Elwyn G**, Durand MA, Song J, Aarts J, Barr PJ, Berger Z, Cochran N, Frosch D, Galasiński D, Gulbrandsen P, Han PKJ, Härter M, Kinnersley P, Lloyd A, Mishra M, Perestelo-Perez L, Scholl I, Tomori K, Trevena L, Witteman HO, Van der Weijden T. A three-talk model for shared decision making: multistage consultation process. *BMJ* 2017; **359**: j4891 [PMID: 29109079 DOI: 10.1136/bmj.j4891]

39 **Stacey D**, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2017; **4**: CD001431 [PMID: 28402085 DOI: 10.1002/14651858.CD001431.pub5]

40 **Trevena LJ**, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PK, King J, Lawson ML, Linder SK, Lipkus I, Ozanne E, Peters E, Timmermans D, Woloshin S. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. *BMC Med Inform Decis Mak* 2013; **13 Suppl 2**: S7 [PMID: 24625237 DOI: 10.1186/1472-6947-13-S2-S7]

41 **Allen LA**, McIlvennan CK, Thompson JS, Dunlay SM, LaRue SJ, Lewis EF, Patel CB, Blue L, Fairclough DL, Leister EC, Glasgow RE, Cleveland JC Jr, Phillips C, Baldridge V, Walsh MN, Matlock DD. Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device: The DECIDE-LVAD Randomized Clinical Trial. *JAMA Intern Med* 2018; **178**: 520-529 [PMID: 29482225 DOI: 10.1001/jamainternmed.2017.8713]

42 **Staszewska A**, Zaki P, Lee J. Computerized Decision Aids for Shared Decision Making in Serious Illness: Systematic Review. *JMIR Med Inform* 2017; **5**: e36 [PMID: 28986341 DOI: 10.2196/medinform.6405]

43 **Chenel V**, Mortenson WB, Guay M, Jutai JW, Auger C. Cultural adaptation and validation of patient decision aids: a scoping review. *Patient Prefer Adherence* 2018; **12**: 321-332 [PMID: 29535507 DOI: 10.2147/PPA.S151833]

44 **Almario CV**, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. *Am J Gastroenterol* 2018; **113**: 58-71 [PMID: 29206816 DOI: 10.1038/ajg.2017.470]

45 **Conrad S**, Hüppe A, Raspe H. [Preference of patients with inflammatory bowel disease regarding information and shared decision-making: results from a cross-sectional survey in Germany]. *Z Gastroenterol* 2012; **50**: 364-372 [PMID: 22467539 DOI: 10.1055/s-0031-1281949]

46 **Baars JE**, Markus T, Kuipers EJ, van der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. *Digestion* 2010; **81**: 113-119 [PMID: 20093836 DOI: 10.1159/000253862]

47 **Mahlich J**, Matsuoka K, Sruamsiri R. Shared Decision Making and Treatment Satisfaction in Japanese Patients with Inflammatory Bowel Disease. *Dig Dis* 2017; **35**: 454-462 [PMID: 28380481 DOI: 10.1159/000471795]

48 **Morishige R**, Nakajima H, Yoshizawa K, Mahlich J, Sruamsiri R. Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients. *Adv Ther* 2017; **33**: 2242-2256 [PMID: 27807816 DOI: 10.1007/s12325-016-0436-0]

49 **Siegel CA**, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making. *Patient* 2016; **9**: 79-89 [PMID: 25963447 DOI: 10.1007/s40271-015-0126-z]

50 **Lofland JH**, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. *Patient Prefer Adherence* 2017; **11**: 947-958 [PMID: 28572722 DOI: 10.2147/PPA.S133222]

51 **Veilleux S**, Noiseux I, Lachapelle N, Kohen R, Vachon L, Guay BW, Bitton A, Rioux JD; iGenoMed Consortium. Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease. *Patient Educ Couns* 2018; **101**: 331-339 [PMID: 28760459 DOI: 10.1016/j.pec.2017.07.028]

52 **O'Connor AM**, Légaré F, Stacey D. Risk communication in practice: the contribution of decision aids. *BMJ* 2003; **327**: 736-740 [PMID: 14512487 DOI: 10.1136/bmj.327.7417.736]

53 **Patel DB**, van Deen WK, Almario CV, Khalil C, Warui E, Bonthala N, Melmed GY, Spiegel BMR. Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. *Inflamm Bowel Dis* 2021; **27**: 1593-1601 [PMID: 33300555 DOI: 10.1093/ibd/izaa311]

54 **Sands BE**, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. *N Engl J Med* 2019; **381**: 1215-1226 [PMID: 31553834 DOI: 10.1056/NEJMoa1905725]

55 **Pouillon L**, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 365-376 [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9]

56 **Meserve J**, Barsky M, Dulai PS. In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. *Best Pract Res Clin Gastroenterol* 2019; **38-39**: 101619 [PMID: 31327408 DOI: 10.1016/j.bpg.2019.05.006]

57 **Kariburyo MF**, Xie L, Teeple A, Tan H, Ingham M. Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers. *Adv Ther* 2017; **34**: 1398-1410 [PMID: 28484953 DOI: 10.1007/s12325-017-0545-4]

58 **Colombel JF**, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010; **362**: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]

59 **Panaccione R**, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology* 2014; **146**: 392-400.e3 [PMID: 24512909 DOI: 10.1053/j.gastro.2013.10.052]

60 **Christophorou D**, Funakoshi N, Duny Y, Valats JC, Bismuth M, Pineton De Chambrun G, Daures JP, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. *Aliment Pharmacol Ther* 2015; **41**: 603-612 [PMID: 25678223 DOI: 10.1111/apt.13102]

61 **Targownik LE**, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. *J Crohns Colitis* 2020; **14**: 1354-1363 [PMID: 32648579 DOI: 10.1093/ecco-jcc/jjaa050]

62 **Bots S**, Gecse K, Barclay M, D'Haens G. Combination Immunosuppression in IBD. *Inflamm Bowel Dis* 2018; **24**: 539-545 [PMID: 29462391 DOI: 10.1093/ibd/izx065]

63 **Chalhoub JM**, Rimmani HH, Gumaste VV, Sharara AI. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease. *Inflamm Bowel Dis* 2017; **23**: 1316-1327 [PMID: 28719541 DOI: 10.1097/MIB.0000000000001203]

64 **Reinisch W**, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. *Gut* 2011; **60**: 780-787 [PMID: 21209123 DOI: 10.1136/gut.2010.221127]

65 **Colombel JF**, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology* 2007; **132**: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]

66 **Feagan BG**, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. *Gastroenterology* 2014; **146**: 681-688.e1 [PMID: 24269926 DOI: 10.1053/j.gastro.2013.11.024]

67 **Hu A**, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. *Clin Gastroenterol Hepatol* 2021; **19**: 1366-1376.e2 [PMID: 32668338 DOI: 10.1016/j.cgh.2020.07.012]

68 **Toruner M**, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008; **134**: 929-936 [PMID: 18294633 DOI: 10.1053/j.gastro.2008.01.012]

69 **D'haens G,** Reinisch W, Satsangi J, Loftus E, Panaccione R, Alperovich G, Kalabic J, Bereswill M, Arikan D, Petersson J, Robinson A. P353 Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry. *J Crohns Colitis* 2017; **11**: S256-257 [DOI: 10.1093/ecco-jcc/jjx002.478]

70 **Osterman MT**, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. *Gastroenterology* 2014; **146**: 941-949 [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025]

71 **Lichtenstein GR**, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. *Am J Gastroenterol* 2012; **107**: 1051-1063 [PMID: 22613901 DOI: 10.1038/ajg.2012.89]

72 **Lemaitre M**, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. *JAMA* 2017; **318**: 1679-1686 [PMID: 29114832 DOI: 10.1001/jama.2017.16071]

73 **Doherty G**, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. *J Crohns Colitis* 2018; **12**: 17-31 [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101]

74 **Larson DW**, Pemberton JH. Current concepts and controversies in surgery for IBD. *Gastroenterology* 2004; **126**: 1611-1619 [PMID: 15168371 DOI: 10.1053/j.gastro.2004.03.063]

**Footnotes**

**Conflict-of-interest statement:** All authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 16, 2022

**First decision:** April 11, 2022

**Article in press:** June 19, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kaur M, United States; Razzaque MS, United States **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 The reasons and fields of application for shared decision making in inflammatory bowel disease treatments.** IBD: inflammatory bowel disease; SDM: shared decision making.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**